Skip to content
DataLookout
Menu

ACTION-001NCT07487662

TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 5 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Study sites: 0 to 1
    • Primary and study completion dates: Mar 17, 2028 to Mar 19, 2028
    • Start date changed from estimate of Mar 18, 2026 to Mar 20, 2026
    • Publications: details revised at 3 of 3 entries
  2. Minor Enrollment increased: 90 → 105 participants
    • Trial arms changed: 4 → 5
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

1-year recurrence-free survival rate
Timeframe: One year

Secondary (3)

major pathological response rate, MPR rate
Objective response rate, ORR
Adverse Events, AE

Arms and interventions

TACE/ablation+ anti-CTLA-4+anti-PD-1 therapyExperimental

Patients assigned to this trial group will receive the first cycle of neoadjuvant sintilimab plus ipilimumab N01 on Day 1. One week thereafter, the multidisciplinary team (MDT) will decide whether to administer TACE or ablation based on lesion characteristics. On Day 22, patients will receive the second cycle of neoadjuvant sintilimab. Surgical resection will be scheduled two weeks after completion of the second cycle of neoadjuvant therapy. Adjuvant sintilimab will commence 4 weeks postoperatively, administered every 3 weeks for up to 15 cycles.

TACE/ablation+ anti-CTLA-4+anti-PD-1+lenvatinib therapyExperimental

Patients assigned to this trial group will receive the first cycle of neoadjuvant sintilimab plus ipilimumab N01 and lenvatinib on Day 1. One week thereafter, the multidisciplinary team (MDT) will decide whether to administer TACE or ablation based on lesion characteristics. On Day 22, patients will receive the second cycle of neoadjuvant sintilimab and lenvatinib. Surgical resection will be scheduled two weeks after completion of the second cycle of neoadjuvant therapy. Adjuvant sintilimab and lenvatinib will commence 4 weeks postoperatively, administered every 3 weeks for up to 15 cycles.

anti-CTLA-4+anti-PD-1 therapyExperimental

Patients assigned to this trial group will receive the first cycle of neoadjuvant sintilimab plus ipilimumab N01 on Day 1. Three weeks thereafter, patients will receive the second cycle of neoadjuvant sintilimab. Surgical resection will be scheduled two weeks after completion of the second cycle of neoadjuvant therapy. Adjuvant sintilimab will commence 4 weeks postoperatively, administered every 3 weeks for up to 15 cycles.

anti-CTLA-4+anti-PD-1+lenvatinib therapyExperimental

Patients assigned to this trial group will receive the first cycle of neoadjuvant sintilimab plus ipilimumab N01 and lenvatinib on Day 1. Three weeks thereafter, patients will receive the second cycle of neoadjuvant sintilimab and lenvatinib. Surgical resection will be scheduled two weeks after completion of the second cycle of neoadjuvant therapy. Adjuvant sintilimab and lenvatinib will commence 4 weeks postoperatively, administered every 3 weeks for up to 15 cycles.

Surgery aloneNo intervention

Patients in this trial arm will undergo resection within 7 days after randomization, followed by regular postoperative follow-up.

Drugs: sintilimab, ipilimumab N01, Lenvatinib

Procedures: TACE, ablation

Sites

1 site in 1 country

  • The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, Guangdong, China